NovoCure Limited is set to release its latest quarterly earnings report on Wednesday, April 29th. Analysts estimate an EPS of -0.51219 for this period.
In the current trading session, NovoCure Limited is priced at $12.43, showing a decrease of -0.385% from the previous close. Trading volume is at $290,044, representing a 15.35% increase compared to the average.
The latest quarterly earnings report for NovoCure Limited, released on February 25th, showed an EPS of -0.41. The consensus estimate for revenue was $173.36 million.
NovoCure Limited reported a net cash outflow of $241.25 million. Notable figures include debt repayment of $560.95 million and operating cash flow of -$18 million.
The company generated revenue of $174.35 million with a gross profit of $132.19 million. Operating expenses totaled $172.59 million, resulting in a net income of -$24.50 million.
Key financial ratios for NovoCure Limited include a quick ratio of 2.9, gross profit margin of 75.82%, and a price-to-book ratio of 4.23.
NovoCure Limited's total assets amount to $804.33 million, with total liabilities at $463.86 million. The company holds $103.39 million in cash and cash equivalents.
This real-time financial report provides a snapshot of NovoCure Limited's current financial standing and performance, offering insights for investors and stakeholders.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.